Evidence map›Paper›PMID 33230623›Full record

ArticleInvestigational new drugs2021

4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer.

Blake A Jacobson, Zeeshan Ahmad, Sierra Chen, Gabriella Waldusky, Maxwell Dillenburg, Emilia Stoian, Daniel A Cambron, Anil J Patel, Manish R Patel, Carston R Wagner and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Blake A JacobsonDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Zeeshan AhmadDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Sierra ChenWayzata High School, Plymouth, MN, USA.
Gabriella WalduskyDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Maxwell DillenburgDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, USA.
Emilia StoianSt. Olaf College, Northfield, MN, USA.
Daniel A CambronFlorida International University, Miami, FL, USA.
Anil J PatelDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Manish R PatelDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
Carston R WagnerDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, USA.
Robert A KratzkeDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA. kratz003@umn.edu.ORCID 0000-0002-1599-7494
University of Minnesota · USFlorida International University · USSt. Olaf College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to suppress 5' cap-mediated translation a highly available inhibitor of the interaction between the 5' mRNA cap and the eIF4E complex has been developed. 4Ei-10 is a member of the class of ProTide compounds and has elevated membrane permeability and is a strong active chemical antagonist for eIF4E. Once taken up by cells it is converted by anchimeric activation of the lipophilic 2-(methylthio) ethyl protecting group and after that Hint1 P-N bond cleavage to N

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungEukaryotic Initiation Factor-4ELung NeoplasmsNucleotidesProdrugsApoptosisCell Line, TumorCell SurvivalDeoxycytidineDrug InteractionsGemcitabineHumans4Ei-10Antineoplastic AgentsDeoxycytidineEukaryotic Initiation Factor-4EGemcitabineNucleotidesProdrugs4Ei-10Cap-dependent translationeIF4EeIF4GNon-small cell lung cancerProTide

Identifiers

PMID33230623
OpenAlexW3107780421

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.